KAS
IBRX icon

Kemnay Advisory Services’s ImmunityBio IBRX Stock Holding History

Kemnay Advisory Services’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.9K Buy
3,524
+422
+14% +$3.19K ﹤0.01% 482
2026
Q1 		$23.8K Buy
+3,102
New +$21.2K ﹤0.01% 573

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Kemnay Advisory Services's IBRX Position: Q2 2026 in Review

Kemnay Advisory Services increased its ImmunityBio (IBRX) stake by 14% in Q2 2026, buying an estimated $3.19K and bringing the position to 3,524 shares worth $30.9K. The position accounts for ﹤0.01% of the portfolio, ranked #482.

Kemnay Advisory Services first reported a position in IBRX in Q1 2026 and has held it in 2 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Kemnay Advisory Services held 3,524 shares of ImmunityBio worth $30.9K as of Q2 2026.
  • Kemnay Advisory Services bought 422 ImmunityBio shares in Q2 2026, an estimated $3.19K.
  • ImmunityBio made up ﹤0.01% of Kemnay Advisory Services's portfolio in Q2 2026, its #482 holding.
  • Kemnay Advisory Services first reported a position in ImmunityBio in Q1 2026 and has held it in 2 quarters since.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Kemnay Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.